Literature DB >> 27955808

Incidence of Hospitalized Stroke in the Czech Republic: The National Registry of Hospitalized Patients.

Petra Sedova1, Robert D Brown2, Miroslav Zvolsky3, Pavla Kadlecova4, Tomas Bryndziar5, Tomáš Kubelka5, Viktor Weiss5, Ondřej Volný5, Josef Bednarik6, Robert Mikulik7.   

Abstract

BACKGROUND: Contemporary stroke incidence data are not available in some countries and regions, including in Eastern Europe. Based on previous validation of the accuracy of the National Registry of Hospitalized Patients (NRHOSP), we report the incidence of hospitalized stroke in the Czech Republic (CR) using the NRHOSP.
METHODS: The results of the prior validation study assessing the accuracy of coding of stroke diagnoses in the NRHOSP were applied, and we calculated (1) the overall incidence of hospitalized stroke and (2) the incidence rates of hospitalized stroke for the three main stroke types: cerebral infarction (International Classification of Diseases Tenth Revision, CI I63), subarachnoid hemorrhage (SAH I60), and intracerebral hemorrhage (ICH I61). We calculated the average annual age- and sex-standardized incidence.
RESULTS: The overall incidence of hospitalized stroke was 241 out of 100,000 individuals. The incidence of hospitalized stroke for the main stroke types was 8.2 cases in SAH, 29.5 in ICH, and 211 in CI per 100,000 individuals. The standardized annual stroke incidence adjusted to the 2000 World Health Organization population for overall stroke incidence of hospitalized stroke was 131 per 100,000 individuals. Standardized stroke incidence for stroke subtypes was 5.7 cases in SAH, 16.7 in ICH, and 113 in CI per 100,000 individuals.
CONCLUSIONS: These studies provide an initial assessment of the burden of stroke in this part of the world. The estimates of hospitalized stroke in the CR and Eastern Europe suggest that ICH is about three times more common than SAH, and hemorrhagic stroke makes up about 18% of strokes.
Copyright © 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Czech Republic; Stroke; epidemiology; incidence; intracerebral hemorrhage; registry; subarachnoid hemorrhage

Mesh:

Year:  2016        PMID: 27955808     DOI: 10.1016/j.jstrokecerebrovasdis.2016.11.006

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  5 in total

1.  Stroke 20 20: Implementation goals for intravenous thrombolysis.

Authors:  Robert Mikulik; Michal Bar; David Cernik; Roman Herzig; Rene Jura; Lubomir Jurak; Jiri Neumann; Daniel Sanak; Svatopluk Ostry; Petr Sevcik; Ondrej Skoda; David Skoloudik; Daniel Vaclavik; Ales Tomek
Journal:  Eur Stroke J       Date:  2021-04-12

2.  Ultrashort Door-to-Needle Time for Intravenous Thrombolysis Is Safer and Improves Outcome in the Czech Republic: Nationwide Study 2004 to 2019.

Authors:  Robert Mikulík; Michal Bar; Silvie Bělašková; David Černík; Jan Fiksa; Roman Herzig; René Jura; Lubomír Jurák; Lukáš Klečka; Jiří Neumann; Svatopluk Ostrý; Daniel Šaňák; Petr Ševčík; Ondřej Škoda; Martin Šrámek; Aleš Tomek; Daniel Václavík
Journal:  J Am Heart Assoc       Date:  2022-05-16       Impact factor: 6.106

3.  Inpatient TIA and stroke care in adult patients in Germany - retrospective analysis of nationwide administrative data sets of 2011 to 2017.

Authors:  Jens Eyding; Dirk Bartig; Ralph Weber; Aristeidis H Katsanos; Christian Weimar; Werner Hacke; Christos Krogias
Journal:  Neurol Res Pract       Date:  2019-12-01

4.  Treat COVID-19, but Not Only COVID-19: Stroke Matters as Well.

Authors:  Petra Sedova; Robert D Brown; Tomas Bryndziar; Jiri Jarkovsky; Ales Tomek; Martin Sramek; Ondrej Skoda; Tereza Sramkova; Simona Littnerova; Robert Mikulik
Journal:  Cerebrovasc Dis       Date:  2021-08-11       Impact factor: 2.762

5.  Study of Stroke Incidence in the Aseer Region, Southwestern Saudi Arabia.

Authors:  Adel A Alhazzani; Ahmed A Mahfouz; Ahmed Y Abolyazid; Nabil J Awadalla; Razia Aftab; Aesha Faraheen; Shamsun Nahar Khalil
Journal:  Int J Environ Res Public Health       Date:  2018-01-26       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.